# A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy

> **NCT01904253** · PHASE2 · TERMINATED · sponsor: **Taiho Oncology, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Small Cell Lung Cancer (SCLC)

## Interventions

- **DRUG:** TAS-102
- **DRUG:** Amrubicin (Japan)
- **DRUG:** Topotecan (Japan/Europe)

## Key facts

- **NCT ID:** NCT01904253
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-07
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** The preliminary data does not suggest any safety signal, but an ad hoc interim analysis showed an imbalance of PFS between the two arms
- **Last updated:** 2024-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01904253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01904253, "A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01904253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*